Transcatheter Aortic Valve Replacement and New Conduction Abnormalities/Permanent Pacemaker Can We Achieve the Intended Implant Depth?∗ by Piazza, Nicolo et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 3 , 2 0 1 6
ª 2 0 1 6 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O UN DA T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 5 . 1 1 . 0 3 4EDITORIAL COMMENTTranscatheter Aortic Valve
Replacement and New Conduction
Abnormalities/Permanent Pacemaker
Can We Achieve the Intended Implant Depth?*Nicolo Piazza, MD, PHD,a Pascal Lauzier, MD, PHD,a Darren Mylotte, MDbI n the spring of 2008, we reported the ﬁrst studyto demonstrate that the depth of the implant of atranscatheter aortic valve correlated with rates of
left bundle branch block and permanent pacemaker
(1). We measured the distance from the ventricular
edge of the CoreValve prosthesis (Medtronic, Minne-
apolis, Minnesota) to the lower edge of the noncoro-
nary cusp to be 9.8  2.8 mm in those with new-onset
left bundle branch block and 5.9  3.7 mm in those
without left bundle branch block (p ¼ 0.005). At that
time, we recommended an implant depth of w6 mm
to mitigate the risk of conduction abnormalities and
the need for a permanent pacemaker. The depth of im-
plantation has also found importance in complications
such as paravalvular aortic regurgitation, coronary
obstruction, malpositioning resulting in embolization
or valve-in-valve, and mitral valve injury.
Positioning of a transcatheter aortic valve is guided
by x-ray ﬂuoroscopy, a 2-dimensional (2D) imaging
modality with the potential for parallax error. As a
result, cardiac structures and/or cardiac devices may
appear foreshortened if perpendicular ﬂuoroscopic
viewing angulations are not obtained. Ideally, both*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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Microport.the aortic annulus and delivery catheter should be
visualized in an optimal angulation. Planar struc-
tures, such as the aortic annular plane and the tip of
the delivery catheter, are optimally visualized when
they are perpendicular to the x-ray source-to-
detector direction. Currently, however, physicians
select a viewing angle perpendicular to either the
aortic annulus or the delivery catheter, but not both
(Figure 1). Proponents aiming for the plane of the de-
livery catheter sacriﬁce the plane of the aortic
annulus; those aiming for the plane of the aortic
annulus sacriﬁce the plane of the delivery catheter.
Given that our implant depths are on the order of
millimeters, foreshortening of the anatomy or delivery
catheter on 2D ﬂuoroscopic imaging can skew the op-
erator’s understanding of the true implant depth. The
effect of foreshortening invariably leads to implant
depths deeper than intended without the operator
noticing on 2D ﬂuoroscopic imaging. A potential so-
lution is to ﬁnd the single ﬂuoroscopic viewing angle
(which exists) that provides both the annulus and
delivery catheter in plane (Figure 2). Our group is
currently conducting clinical research in this area.SEE PAGE 244In this issue of JACC: Cardiovascular Interventions,
Husser et al. (2) examined the incidence and predictors
of new permanent pacemaker implantation (PPI) and
new-onset conduction abnormalities (i.e., left bundle
branch block [LBBB]/right bundle branch block
[RBBB]) after SAPIEN 3 (Edwards Lifesciences, Irvine,
California) implantation. The authors reported that 34
of 208 (16%) patients required a new PPI for appro-
priate indications including third-degree atrioven-
tricular block, high second-degree atrioventricular
FIGURE 1 Two Methods Currently Used to Implant Transcatheter Aortic Valves
(A) Proponents aiming for the plane of the annulus lose the plane of the delivery catheter. In this case, the delivery catheter is foreshortened.
(B) Proponents aiming for the plane of the delivery catheter lose the plane of the aortic annulus. In this case, the aortic annulus is foreshortened.
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256block, and symptomatic bradycardia. The ﬂuctuation
in the rate of new PPIs across consecutive patients is
noteworthy; it nearly doubled from 13% in the ﬁrst 70
patients to 22% in the last 70 patients. This observation
may be related to chance and sample size, but also
brings to mind the heterogeneous PPI rates observed
across centers for a particular device, notwithstanding
the inconsistent indications for a new PPI after TAVR.
Speciﬁc guidelines for PPI after TAVR are lacking and is
an area that requires more study and collaborative
efforts.
The authors also noted that 1 of 3 patients re-
quired a new PPI or developed new-onset conductionFIGURE 2 Scenario in Which Both the Aortic Annulus and Delivery C
Neither the aortic annulus or delivery catheter are foreshortened.abnormalities (LBBB or RBBB). These rates de-
ﬁnitely appear higher than expected for conventional
balloon-expandable platforms. Whereas previous
studies of SAPIEN XT reported new PPI rates between
5% and 12% (3,4), recent studies of the SAPIEN 3
document rates up to 26% (5–7). Although retrospec-
tive comparisons have been published, prospective
head-to-head comparison data for SAPIEN XT and
SAPIEN 3 are not and will not be available.
Patient-, operator- and device-related factors can
contribute to the development of conduction abnor-
malities and the need for PPI after TAVR. More spe-
ciﬁcally, the authors found an association betweenatheter Are in Plane
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257new PPI and the following variables: pre-existing
RBBB, atrial ﬁbrillation, heart rate, baseline QRS
duration, and implant depth. For the combined
endpoint of new PPI and new-onset conduction
abnormalities, the following independent predictors
were noted: pre-existing QRS duration, implant
depth, and the degree of oversizing.
The predictors of new PPI and/or conduction
abnormalities (e.g., pre-existing RBBB, atrial ﬁbrilla-
tion, oversizing, implant depth) reported in this study
are not surprising and have been reported elsewhere,
including SAPIEN XT studies. The important ﬁnding
of this study lies in the higher-than-expected rates of
new PPI and/or conduction abnormalities for the
SAPIEN 3.
Similar to the SAPIEN XT, the SAPIEN 3 frame is
constructed of cobalt-chromium alloy. The nominal
frame height of the SAPIEN 3 device is longer and
undergoes greater foreshortening during deployment
than the SAPIEN XT (e.g., for a 26-mm valve size, the
SAPIEN 3 frame height is 20 mm and foreshortens 8
mm during deployment vs. the SAPIEN XT frame
height of 17.2 mm that foreshortens 2 mm) (8).
Changes in frame design can inﬂuence implant depth.
In this case, operators may be inclined to implant the
SAPIEN 3 “deeper” into the left ventricular outﬂow
tract to avoid potential coronary arterial complica-
tions. Furthermore, the need to take into account the
greater foreshortening characteristics of the SAPIEN 3
can complicate position accuracy.
The beneﬁts of superior sealing afforded by the new
SAPIEN 3 skirt appear to be counterbalanced by an
increased incidence of conduction abnormalities (9).
The association between either paravalvular aortic
regurgitation or new PPI/conduction abnormalities
and adverse clinical outcomes after transcatheter
aortic valve replacement (TAVR) is controversial. New-
onset LBBB after surgical aortic valve replacement in
low-risk patients has been linked to sudden cardiac
death, syncope, and the need for a permanent pace-
maker at 1-year follow-up (10).
Until now, newer generation TAVR devices appear
to have positive effects on clinical outcomes. The
current ﬁndings of Husser et al. (2) highlight that new
device iterations, although designed with good in-
tentions, can be associated with untoward and un-
expected clinical outcomes. These ﬁndings reinforce
the argument that new TAVR devices need to be
prospectively studied using systematic and robust
clinical protocols.
The clinical implications and practicality of the
current study ﬁndings need to be addressed.
Although the authors conclude that “avoidance ofdeep implant depth and extreme oversizing may
avoid PPI and conduction abnormalities,” several
important questions remain. What is the deﬁnition of
“deep implant depth” and “extreme oversizing”? The
implant depth was guided by the ﬂuoroscopic
viewing angle with the aortic annulus in plane while
the measured implant depth was performed using a
different ﬂuoroscopic viewing angle with the pros-
thesis in plane. This is counterintuitive—the ﬂuoro-
scopic viewing angle used to target a particular
implant depth during deployment is then not used to
measure implant depth. The paradox stems from the
potential foreshortening of the annulus and/or device
on 2D ﬂuoroscopic imaging as described above. In
fact, the only accurate method to measure the true
implant depth is when both the annulus and device
are orthogonal to the viewing plane. Up until now, no
study has reported the depth of implant in this way.
The authors reported the depth of implant as the
percentage of the prosthesis lying below the annular
plane. The mean implant depth was 26  7%. Given
that the frame height differs across device sizes, the
authors should have reported the depth of implant
according to device size. Without this information,
the reader cannot translate the current study results
to clinical practice. Reporting the implant depth in
units of millimeters would allow further analyses to
suggest a maximum cut-off depth to mitigate the risk
of new PPI and conduction abnormalities.
A peculiar notion was that 12% of patients were
“undersized” according to area. This implies that the
device was smaller (on average by 9%) than the aortic
annulus. This goes against the underlying principles
of radial force and the need for oversizing to anchor
transcatheter aortic valves. What is known is that
anchoring and sealing of transcatheter aortic valves
occurs across the region of the native aortic valve
leaﬂets, annulus, and left ventricular outﬂow tract.
The notion of “undersizing” by the authors suggests
that further work is needed to better understand the
anchoring mechanisms and oversizing principles
associated with the SAPIEN 3 device.
As we move toward younger and lower surgical
risk patients, the incidence, mechanisms, implica-
tions, and potential solutions to lessen the risks of
conduction abnormalities and need for PPI following
TAVR need to be further elucidated.
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